5 Key Takeaways

• 1

  A study identified limitations in detecting MET exon 14 skipping variants in non-small cell lung cancer due to assay design and bioinformatics.

• 2

  Tissue testing showed high performance in MET exon 14 testing, while liquid biopsy analysis had lower accuracy and higher false-negative rates.

• 3

  Researchers analyzed 379 NSCLC samples and found 171 distinct MET exon 14 and splice-site variants, highlighting the complexity of testing.

• 4

  RNA testing confirmed exon 14 skipping in 107 of 114 variants, revealing pitfalls in DNA-based testing that missed large deletions.

• 5

  The study suggests that combining DNA- and RNA-based testing may reduce missed clinically relevant variants and emphasizes assay validation.